Exicure(US:XCUR)2025-11-07 21:07Financial Performance - The net loss for Q3 2025 was $2.4 million, compared to a net loss of $1.1 million in Q3 2024, marking an increase in net loss of 118.2%[7] - Total revenue for the nine months ended September 30, 2025, was $0, compared to $500,000 for the same period in 2024, indicating a significant decline in revenue[16] - The company reported total operating expenses of $2.4 million for Q3 2025, a decrease of 7% from $2.6 million in Q3 2024[16] - The company recognized a loss of $246,000 related to the change in the fair value of its contingent liability during Q3 2025[6] Cash Position - Cash and cash equivalents decreased to $4.4 million as of September 30, 2025, down from $12.5 million as of December 31, 2024, representing a decline of 64.8%[3] - Management indicated that existing cash and cash equivalents are insufficient to fund operations, necessitating substantial additional financing in the short term[8] Expenses - Research and development expenses for Q3 2025 were $0.9 million, compared to $0 for Q3 2024, indicating the company began incurring R&D costs following the acquisition of GPCR Therapeutics USA Inc.[4] - General and administrative expenses increased to $1.5 million in Q3 2025 from $1.4 million in Q3 2024, reflecting an increase of 7.1% primarily due to costs associated with the GPCR USA acquisition[5] Assets and Equity - The company’s total assets as of September 30, 2025, were $15.3 million, a slight increase from $15.1 million as of December 31, 2024[14] - Stockholders' equity increased to $6.9 million as of September 30, 2025, from $6.8 million as of December 31, 2024, reflecting a growth of 2.3%[14]